首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Critical Overview of the Risk Scoring Systems to Predict Non-Responsiveness to Intravenous Immunoglobulin in Kawasaki Syndrome
【2h】

Critical Overview of the Risk Scoring Systems to Predict Non-Responsiveness to Intravenous Immunoglobulin in Kawasaki Syndrome

机译:预测川崎综合症对静脉免疫球蛋白无反应性的风险评分系统的综述

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Kawasaki syndrome (KS) is the most relevant cause of heart disease in children living in developed countries. Intravenous immunoglobulin (IVIG) has a preventive function in the formation of coronary artery abnormalities and a poor strictly-curative action in established coronary damage. More than two decades ago, the Harada score was set to assess which children with KS should be subject to administration of IVIG, evaluating retrospectively a large cohort of patients with regard to age, sex and laboratory data. Nowadays, high dose IVIG is administered to all children with a confirmed diagnosis of KS, but a tool for predicting non-responsiveness to the initial infusion of IVIG has not been found. The prediction of IVIG resistance is a crucial issue, as recognising these high-risk patients should consent the administration of an intensified initial treatment in combination with IVIG in order to prevent coronary injuries. Few reports have focused on factors, referring to both clinical parameters and laboratory data at the onset of KS, in order to predict which patients might be IVIG non-responsive. We have analysed three different risk scores which were formulated to predict IVIG resistance in Japanese children with typical KS, but their application in non-Japanese patients or in those with incomplete and atypical patterns of the disease has been studied in a fragmentary way. Overall, our analysis showed that early and definite ascertainment of likely IVIG non-responders who require additional therapies reducing the development of coronary artery involvement in children with KS is still a challenge.
机译:川崎综合征(KS)是生活在发达国家儿童中最相关的心脏病原因。静脉内免疫球蛋白(IVIG)在形成冠状动脉异常中具有预防功能,在确定的冠状动脉损伤中具有严格的严格治疗作用。二十多年前,制定了Harada评分以评估哪些KS儿童应接受IVIG的治疗,并就年龄,性别和实验室数据进行回顾性评估。如今,已对确诊为KS的所有儿童均给予高剂量的IVIG,但尚未发现预测IVIG初始输注无反应的工具。 IVIG耐药性的预测是一个至关重要的问题,因为认识到这些高危患者应同意与IVIG联合使用强化初始治疗,以预防冠心病。为了预测哪些患者可能对IVIG无反应,很少有报告关注于因素,同时参考KS发作时的临床参数和实验室数据。我们分析了三种不同的风险评分,这些评分旨在预测患有典型KS的日本儿童的IVIG抵抗力,但已经零碎地研究了其在非日本患者或该疾病的不完全和非典型模式中的应用。总体而言,我们的分析表明,早期明确确定需要其他治疗以减少KS儿童冠状动脉受累发展的IVIG无应答者仍然是一个挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号